PL3281952T3 - Antygen związany z reumatoidalnym zapaleniem stawów - Google Patents

Antygen związany z reumatoidalnym zapaleniem stawów

Info

Publication number
PL3281952T3
PL3281952T3 PL17189028T PL17189028T PL3281952T3 PL 3281952 T3 PL3281952 T3 PL 3281952T3 PL 17189028 T PL17189028 T PL 17189028T PL 17189028 T PL17189028 T PL 17189028T PL 3281952 T3 PL3281952 T3 PL 3281952T3
Authority
PL
Poland
Prior art keywords
rheumatoid arthritis
antigen associated
antigen
rheumatoid
arthritis
Prior art date
Application number
PL17189028T
Other languages
English (en)
Inventor
Manuela Kaspar
Kathrin Schwager
Eveline Trachsel
Original Assignee
Philogen S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philogen S.P.A. filed Critical Philogen S.P.A.
Publication of PL3281952T3 publication Critical patent/PL3281952T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
PL17189028T 2007-10-30 2008-10-27 Antygen związany z reumatoidalnym zapaleniem stawów PL3281952T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US98360607P 2007-10-30 2007-10-30
EP17189028.8A EP3281952B1 (en) 2007-10-30 2008-10-27 An antigen associated with rheumatoid arthritis
EP08844563.0A EP2209805B1 (en) 2007-10-30 2008-10-27 An antigen associated with rheumatoid arthritis
PCT/EP2008/009070 WO2009056268A1 (en) 2007-10-30 2008-10-27 An antigen associated with rheumatoid arthritis

Publications (1)

Publication Number Publication Date
PL3281952T3 true PL3281952T3 (pl) 2020-11-16

Family

ID=40282320

Family Applications (2)

Application Number Title Priority Date Filing Date
PL08844563T PL2209805T3 (pl) 2007-10-30 2008-10-27 Antygen związany z reumatoidalnym zapaleniem stawów
PL17189028T PL3281952T3 (pl) 2007-10-30 2008-10-27 Antygen związany z reumatoidalnym zapaleniem stawów

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL08844563T PL2209805T3 (pl) 2007-10-30 2008-10-27 Antygen związany z reumatoidalnym zapaleniem stawów

Country Status (18)

Country Link
US (4) US8222377B2 (pl)
EP (3) EP3783019A1 (pl)
JP (3) JP5106635B2 (pl)
KR (3) KR101608544B1 (pl)
CN (2) CN103396483B (pl)
AU (1) AU2008317941B2 (pl)
BR (1) BRPI0818272B8 (pl)
CA (1) CA2704296C (pl)
DK (2) DK3281952T3 (pl)
ES (2) ES2807753T3 (pl)
HU (2) HUE050038T2 (pl)
MX (1) MX2010004726A (pl)
NO (1) NO2209805T3 (pl)
PL (2) PL2209805T3 (pl)
PT (2) PT2209805T (pl)
RU (2) RU2486198C2 (pl)
SI (2) SI2209805T1 (pl)
WO (1) WO2009056268A1 (pl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070084556A1 (en) 2005-10-14 2007-04-19 Langseder Neal E Method of applying a label to a squeeze tube
CA2682851C (en) 2007-04-02 2017-01-17 Philogen S.P.A. A novel antigen associated with the neovasculature of tumour metastases
US10202442B2 (en) 2007-07-25 2019-02-12 Philogen S.P.A. Antigen associated with lung cancers and lymphomas
RU2486198C2 (ru) 2007-10-30 2013-06-27 Филоджен С.П.А. Антиген, ассоциированный с ревматоидным артритом
ES2549362T3 (es) 2009-01-07 2015-10-27 Philogen S.P.A. Antígenos asociados a endometriosis
EP2947096B1 (en) 2009-08-05 2018-11-28 Philogen S.p.A. Targeting of bone marrow neovasculature
EP2736535B1 (en) * 2011-07-27 2018-10-17 Philogen S.p.A. Il-12 immunoconjugate
KR20150038012A (ko) 2012-08-08 2015-04-08 로슈 글리카트 아게 인터루킨-10 융합 단백질 및 그의 용도
TWI499426B (zh) * 2012-09-27 2015-09-11 Philogen Spa 與發炎性腸病有關之抗原
HUE044927T2 (hu) 2012-10-03 2019-11-28 Philogen Spa Ellenanyag-konjugátum, gyulladásos bélbetegség kezelésében történõ alkalmazásra
MX2016010174A (es) * 2014-02-06 2016-11-15 Hoffmann La Roche Proteinas de fusion de interleucina-10 y usos de las mismas.
GB201507908D0 (en) 2015-05-08 2015-06-24 Philogen Spa IL2 and TNF immunoconjugates
MX2018000687A (es) 2015-07-16 2018-08-01 Philogen Spa Inmunoconjugados de il22.
US20190309060A1 (en) 2016-01-15 2019-10-10 Philogen S.P.A. Intestinal antigens for pharmacodelivery applications
JP2017197558A (ja) * 2017-06-07 2017-11-02 フィロゲン エスピーエー 炎症性腸疾患に関連する抗原
CN110997718B (zh) 2017-06-07 2023-11-10 菲洛根股份公司 血管内皮生长因子/抗纤连蛋白抗体融合蛋白
US12006345B2 (en) 2019-02-21 2024-06-11 Xencor, Inc. Untargeted and targeted IL-10 Fc-fusion proteins
WO2020181235A1 (en) * 2019-03-06 2020-09-10 Deka Biosciences, Inc. Il-10 variant molecules and methods of treating inflammatory disease and oncology
WO2020249757A1 (en) 2019-06-14 2020-12-17 Philogen S.P.A Immunoconjugates comprising a single chain diabody and interleukin-15 or interleukin-15 and a sushi domain of interleukin-15 receptor alpha
KR20230096959A (ko) 2020-07-20 2023-06-30 데카 바이오사이언시즈, 인크. Il-10을 포함하는 이중 시토카인 융합 단백질
WO2022018126A1 (en) 2020-07-22 2022-01-27 Philogen S.P.A. Treatment of pulmonary hypertension
CN113480636B (zh) * 2021-06-23 2023-11-03 烟台科瑞斯生物技术有限责任公司 重组人纤连蛋白及其制备、活性测定和稳定性实验方法
WO2023175077A1 (en) 2022-03-17 2023-09-21 Philogen S.P.A Anti-ed-a antibodies for the treatment of pulmonary hypertension

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IT1217724B (it) 1988-05-26 1990-03-30 Ist Naz Ric Sul Cancro Anticorpo monoclonale specifico per una sequenza di fibronettina espressa in cellule trasformate ibridoma secernente tale anticorpo e impiego dell'anticorpo monoclonale per la diagnosi di tumori
US5420012A (en) 1989-05-08 1995-05-30 Locus Genex Oy Method for the detection of reactive conditions
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9206318D0 (en) 1992-03-24 1992-05-06 Cambridge Antibody Tech Binding substances
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0580859A4 (en) * 1991-03-26 1994-09-14 Otsuka Pharma Co Ltd Anti-eda monoclonal antibody
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
US6492160B1 (en) 1991-05-15 2002-12-10 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6225447B1 (en) 1991-05-15 2001-05-01 Cambridge Antibody Technology Ltd. Methods for producing members of specific binding pairs
US5962255A (en) 1992-03-24 1999-10-05 Cambridge Antibody Technology Limited Methods for producing recombinant vectors
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5872215A (en) 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
DK0672142T3 (da) 1992-12-04 2001-06-18 Medical Res Council Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
US5644033A (en) 1992-12-22 1997-07-01 Health Research, Inc. Monoclonal antibodies that define a unique antigen of human B cell antigen receptor complex and methods of using same for diagnosis and treatment
AU6098994A (en) 1993-01-27 1994-08-15 Duke University Methods and agents for the diagnosis and treatment of rheumatoid arthritis
US6054312A (en) * 1997-08-29 2000-04-25 Selective Genetics, Inc. Receptor-mediated gene delivery using bacteriophage vectors
DE69941267D1 (de) 1998-12-10 2009-09-24 Bristol Myers Squibb Co Proteingerüste für antikörper-nachahmer und andere bindende proteine
WO2001062298A2 (en) 2000-02-24 2001-08-30 Philogen S.R.L. Compositions and methods for treatment of angiogenesis in pathological lesions
US20030152572A1 (en) * 2000-04-06 2003-08-14 Yoshimi Homma Diagnostic and therapeutic agents for rheumatoid arthritis
AU5867901A (en) 2000-05-04 2001-11-12 Philogen S.R.L. Method for detecting tumors
PL364358A1 (pl) * 2000-09-07 2004-12-13 Schering Ag Receptor domeny ED b fibronektyny (II)
US6780594B2 (en) 2000-09-25 2004-08-24 Schering Aktiengesellschaft Method for in vitro diagnosis of endometriosis
IT1317108B1 (it) 2000-12-06 2003-05-26 Philogen Srl Processo per la selezione di frammenti anticorporali anti-angiogenesi,frammenti anticorpali anti-angiogenesi cosi' ottenuti e loro uso.
US20020187100A1 (en) 2000-12-21 2002-12-12 David Rizzieri Anti-tenascin monoclonal antibody therapy for lymphoma
EP1224943A1 (en) 2001-01-19 2002-07-24 Crucell Holland B.V. Fibronectin as a tumor marker detected by phage antibodies
US7585491B2 (en) 2002-12-13 2009-09-08 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
GB0209896D0 (en) * 2002-04-30 2002-06-05 Molmed Spa Conjugate
AU2003238284A1 (en) 2002-06-21 2004-01-06 Duke University Anti-tenascin antibody fragments and minibodies for treatment of lymphoma
JP4790413B2 (ja) * 2002-10-08 2011-10-12 イミューノメディクス、インコーポレイテッド 抗体療法
US20040202666A1 (en) 2003-01-24 2004-10-14 Immunomedics, Inc. Anti-cancer anthracycline drug-antibody conjugates
US7560095B2 (en) 2003-04-22 2009-07-14 A & G Pharmaceutical, Inc. Cancer specific monoclonal antibodies
WO2005009366A2 (en) 2003-07-24 2005-02-03 Cornell Research Foundation, Inc. Restoring vascular function
CA2533878A1 (en) 2003-07-29 2005-09-22 Immunomedics, Inc. Fluorinated carbohydrate conjugates
EP1702069A2 (en) 2004-01-05 2006-09-20 EMD Lexigen Research Center Corp. Interleukin-12 targeted to oncofoetal fibronectin
AU2005280528B2 (en) * 2004-07-30 2010-12-23 Adeza Biomedical Corporation Oncofetal fibronectin as a marker for disease and other conditions and methods for detection of oncofetal fibronectin
US7785591B2 (en) 2004-10-14 2010-08-31 Morphosys Ag Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies
PT1817345E (pt) 2004-11-09 2009-08-21 Philogen Spa Anticorpos contra a tenascina c
WO2006067633A2 (en) * 2004-12-23 2006-06-29 Molmed Spa Conjugation product
ATE459648T1 (de) * 2005-05-11 2010-03-15 Philogen Spa Fusionsprotein von antikörper l19 gegen fibronectin ed-b und interleukin 12
WO2007001940A2 (en) 2005-06-23 2007-01-04 Emory University Imaging agents
EP2015775B1 (en) 2006-05-03 2011-06-01 Bayer Schering Pharma Aktiengesellschaft Combination of an anti edb fibronectin domain antibody l19-sip and an anti-egfr antibody
EA200802289A1 (ru) * 2006-05-08 2009-04-28 Филоджен Спа Направляемые к мишени антителами цитокины для терапии
CA2682851C (en) 2007-04-02 2017-01-17 Philogen S.P.A. A novel antigen associated with the neovasculature of tumour metastases
ES2534726T3 (es) * 2007-07-25 2015-04-27 Philogen S.P.A. Antígeno ED-A del fibrinógeno que está asociado con linfomas
US10202442B2 (en) 2007-07-25 2019-02-12 Philogen S.P.A. Antigen associated with lung cancers and lymphomas
RU2486198C2 (ru) 2007-10-30 2013-06-27 Филоджен С.П.А. Антиген, ассоциированный с ревматоидным артритом
WO2010078945A2 (en) 2009-01-07 2010-07-15 Philogen S.P.A. Cancer treatment
ES2549362T3 (es) 2009-01-07 2015-10-27 Philogen S.P.A. Antígenos asociados a endometriosis
BR112013007160A2 (pt) 2010-09-29 2016-06-14 Philogen Spa ligante tiazolidina para a conjugação de fármacos a anticorpos
EP2736535B1 (en) 2011-07-27 2018-10-17 Philogen S.p.A. Il-12 immunoconjugate
HUE044927T2 (hu) 2012-10-03 2019-11-28 Philogen Spa Ellenanyag-konjugátum, gyulladásos bélbetegség kezelésében történõ alkalmazásra
EP2988784A1 (en) 2013-04-25 2016-03-02 Philogen S.p.A. Antibody-drug conjugates
AU2014257906A1 (en) 2013-04-26 2015-12-10 Philogen S.P.A. IL4 conjugated to antibodies against extracellular matrix components
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card

Also Published As

Publication number Publication date
PT3281952T (pt) 2020-07-23
US20120244114A1 (en) 2012-09-27
RU2649368C2 (ru) 2018-04-02
MX2010004726A (es) 2010-05-20
CN101918443A (zh) 2010-12-15
JP2013040183A (ja) 2013-02-28
EP2209805B1 (en) 2017-09-06
KR102002739B1 (ko) 2019-07-23
JP5106635B2 (ja) 2012-12-26
JP6154594B2 (ja) 2017-06-28
ES2646228T3 (es) 2017-12-12
JP6198703B2 (ja) 2017-09-20
JP2015091799A (ja) 2015-05-14
BRPI0818272B8 (pt) 2021-05-25
US9556257B2 (en) 2017-01-31
NO2209805T3 (pl) 2018-02-03
RU2486198C2 (ru) 2013-06-27
CA2704296C (en) 2017-08-22
EP3281952B1 (en) 2020-06-24
EP3783019A1 (en) 2021-02-24
US20170298122A1 (en) 2017-10-19
CN103396483A (zh) 2013-11-20
KR20160039305A (ko) 2016-04-08
PL2209805T3 (pl) 2018-01-31
HUE050038T2 (hu) 2020-11-30
RU2013115891A (ru) 2014-10-20
CN101918443B (zh) 2013-07-17
KR20180027640A (ko) 2018-03-14
US10385121B2 (en) 2019-08-20
KR101608544B1 (ko) 2016-04-01
US8222377B2 (en) 2012-07-17
CN103396483B (zh) 2016-11-23
KR101836968B1 (ko) 2018-03-12
DK3281952T3 (da) 2020-08-03
PT2209805T (pt) 2017-11-14
ES2807753T3 (es) 2021-02-24
WO2009056268A1 (en) 2009-05-07
SI3281952T1 (sl) 2020-09-30
DK2209805T3 (en) 2017-10-16
BRPI0818272A2 (pt) 2015-04-14
BRPI0818272B1 (pt) 2021-01-12
HUE037036T2 (hu) 2018-08-28
SI2209805T1 (sl) 2017-11-30
CA2704296A1 (en) 2009-05-07
US20190352384A1 (en) 2019-11-21
JP2011502137A (ja) 2011-01-20
AU2008317941B2 (en) 2015-01-22
KR20100101587A (ko) 2010-09-17
EP3281952A1 (en) 2018-02-14
RU2010121874A (ru) 2011-12-10
EP2209805A1 (en) 2010-07-28
AU2008317941A1 (en) 2009-05-07
US20100260707A1 (en) 2010-10-14

Similar Documents

Publication Publication Date Title
PL2209805T3 (pl) Antygen związany z reumatoidalnym zapaleniem stawów
GB0708002D0 (en) Antibodies
PT2146745E (pt) Anticorpo pentaespecífico
EP2138576A4 (en) ANTI-CLAUDIN-4 ANTIBODY
ZA201002275B (en) Il-23 antibodies
EP2115625A4 (en) CHANGES TO A DOCUMENT
IL204537A0 (en) Modified antibody constant region
SI2200700T1 (sl) Nova protitelesa
EP2196861A4 (en) TONER
EP2204699A4 (en) TONER
EP2241578A4 (en) ANTI-CLDN6 ANTIBODIES
IL200012A0 (en) Anti-robo4 antibodies and uses therefor
IL200168A0 (en) Monoclonal anti-cxcl13 antibodies
GB0718737D0 (en) Antibodies
IL205073A0 (en) Anti-bst2 antibody
ZA200900954B (en) Ant-C5aR antibodies with improved properties
GB0702888D0 (en) Novel Antibodies
EP2015785A4 (en) ANTIGEN AGRM2
WO2012018776A9 (en) Treating rheumatoid arthritis with anti-il-19 antibody
WO2011047073A9 (en) Assessing rheumatoid arthritis
EP2264071A4 (en) ANTIBODY WITH AN IMMUNE-REINFORCING FUNCTION
GB0911770D0 (en) Antibody
GB0709047D0 (en) Autoimmune antigens
GB0724185D0 (en) Antibodies
GB0819113D0 (en) An antibody